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Cholera toxin (CT) is composed of a monomeric A subunit (CTA) and a pentameric B subunit (CTB). After binding of CTB to cell surface gan gliosides, CTA acts to catalyze the ADP ribo sylation of the intracellular G protein subunit Gs, which then dissociates from Gsdimer and activates adenylate cyclase. This results in the induction of cAMP and activation of cAMP dependent protein kinase A. Enzymatically active CT, as well as other ligands that induce cAMP production, can inhibit the production of IL12 from monocytes and DCs (1, 2) . CT also inhibits expression of IL121 and 122 receptors on activated T cells, suppresses the function of Th1 but not Th2 T cell clones (3) , and drives the dif ferentiation of Th2 and IL10-producing Tr1 T cells in vitro (4) . In vivo, CT inhibits the production of both IL12 and IFN in mice given LPS systemically (5) . Given orally with most soluble protein antigens, CT preferentially drives Th2 responses locally and systemically, which is associated with production of IgA and IgG1>IgG2a antibodies; and after repeated oral dosing, CT induces high IgE levels to coad ministered antigens that results in anaphylaxis to CT to block IL12 production and responsiveness likely con tributes to its ability to drive Th2 responses when given orally with protein antigens (1) .
Although it has been reported that CTB alone can down regulate IL12 expression (7) , its inhibitory potency is a frac tion of that caused by CT holotoxin (5) . This indicates that the ability of CT to suppress IL12 production is primarily dependent on the enzymatically active A subunit, as is its ability to act as an adjuvant in vivo (1, 2) . In addition, the suppression of IL12 by ligandmediated activation of Gs protein-coupled receptors, such as those for prostaglandin E 2 , histamine, 2adrenergic agonists, adenosine, cannabi noids, and opiates, as well as by the cellpermeable cAMP ana logue dbcAMP, suggests that the direct induction of cAMP by Gs protein activation plays a key role in CTmediated IL12 suppression (1, 2) . However, the downstream effects of Gs protein-induced cAMP on the signaling pathways required for IL12 production are not clear.
RESULTS AND DISCUSSION Gs protein-mediated inhibition of IL-12 production by cDCs
Prior studies demonstrated the ability of CT to inhibit the pro duction of IL12 from human monocytes and monocytederived DCs (5) . We initially determined whether this also applied to freshly isolated mouse conventional DCs (cDCs), and whether it extended to other Gs protein agonists. CT, as well as agonists for 2adrenergic receptor (salbutamol), and the adenosine A2a receptor (CGS 21680; 2p[2Carboxyethyl] phenethylamino 5Nethylcarboxamidoadenosine hydrochloride) suppressed the production of both IL12p40 and IL12p70 from spleen cDCs stimulated with SAC and IFN (Fig. S1 ), whereas IL10 pro duction was not suppressed (unpublished data).
CT inhibits the production of IL-12 after infection with Toxoplasma gondii in vivo CT has been shown to induce Th2 responses after oral admin istration with soluble protein antigens; however, because CT is normally given with inactivated proteins, the extent to which CT can modify the helper T (Th) cell phenotype dur ing the induction of strong Th1 responses, as occurs after infec tion with intracellular pathogens, is not clear. Furthermore, when given intranasally, or orally with less purified antigens, CT has been reported to induce Th1 and Th2 responses (8, 9) . Therefore, we decided to test the ability of CT to modify Th1 responses in mice during systemic infection of BALB/c mice with a high dose of the ME49 strain of T. gondii. In this model, mice develop IL12-dependent Th1 responses that clear the infection with 100% survival (10) . As shown in Fig. 1 , systemic administration of CT during the course of infection resulted in 100% mortality with nearly identical kinetics to that occurring after systemic neutralization of IL12 (Fig. 1 A) . In addition, parasite loads were high (Fig. 1 B) and serum levels of IL12 and IFN were suppressed in both CT and anti-IL12-treated groups (Fig. 1 C) , consistent with CT having a dominant inhibitory effect on IL12 production and the induction of Th1 responses to this infection. subsequent antigenic challenge (6) . Together with several addi tional effects on immune and nonimmune cells, the ability of 
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showed a 20-30% reduction of total cell numbers in the spleen, there was a dramatic preferential reduction of CD11c + CD8 + cDCs compared with CD11b + cDCs (Fig. 2 A) and other lymphocyte compartments (Fig. 2 B) . The loss of CD8 + cDCs was not caused by apoptosis (Fig. S2) ; was transient, with cell numbers returning to normal levels by day 6; and was dose dependent, with 5 µg of CT having maximal CT treatment results in a loss of CD8 + cDCs Although it is likely that a variety of cells produce IL12 dur ing infection with T. gondii in vivo, including macrophages (11) and neutrophils (12) , CD8 + cDCs are thought to be one major source of this essential cytokine (13) . We therefore asked whether CT administration affects IL12 production by cDC subsets in vivo. Although mice treated with CT (Fig. S2) . the serum. Prior studies have shown that CD8 + cDCs are a significant source of IL12 under these conditions (13) , and that IFN production after LPS administration can be blocked with antibodies to IL12p40 (5). We found that low doses of CT (0.5 µg) consistently suppressed both IL12 and IFN production in response to LPS (Fig. S3) . Furthermore, the total percentages of CD4 + and CD8 + T cells, as well as CD19 + B cells, were unchanged after CT treatment (Fig. 2 B) . These studies suggest that systemic administration of CT has two dosedependent effects in vivo, one resulting in the loss of CD8 + cDCs and the other resulting in the inhibition of IL12 production by DCs and possibly other cells.
CT blocks IFN regulatory factor (IRF) 8-chromatin interactions
In our initial studies using human monocytes stimulated with LPS alone or LPS and IFN, CT had no effect on the acti vation of signaling molecules positively regulating IL12 pro duction, such as NFB, STAT1, or the mitogenactivated and 0.5 µg of CT having minimal effects (Fig. S3 B) . More over, no difference in the viability of splenocytes or periph eral blood cells from CTtreated versus PBStreated controls or CTBtreated mice was found (unpublished data). Treatment with CTB had no effect on CD8 + cDC numbers (unpub lished data), indicating that ADP ribosylate activity of CTA was required for the loss of CD8 + cDCs.
The loss of IL12-producing CD8 + cDCs may con tribute to the effects seen with CT in T. gondii infection. To address this issue more directly, we infected mice after treat ment with 0.5 µg of CT, which has only minor effects on CD8 + cDC numbers. At this dose, the effects of CT on the course of T. gondii infection were highly variable, yet in some experiments we observed a significant effect on survival and parasite load, despite only a minor change in CD8 + cDC numbers ( Fig. S3 and not depicted). To test the possibility that CT may affect IL12 production independent of CD8 + cDC loss, we gave graded doses of CT to mice, administered LPS systemically, and measured IL12 and IFN levels in 
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protein kinases (MAPKs) p38 and JNK (unpublished data). In addition, CT had no effect on the activation of extracellular signalregulated kinase MAPK, which is a known negative regulator of IL12 expression (unpublished data). Moreover, CT treatment did not affect the surface expression of Toll like receptor (TLR)4 or IFN receptor on LPSstimulated or unstimulated monocytes (unpublished data) or the IFN receptor signaling pathway, as IFN-induced upregulation of HLADR and CD40 was unaffected (unpublished data).
We next focused our study on the effect of CT on the function of IRF8, which is a transcription factor expressed by DCs, macrophages, granulocytes, and B cells; it is a positive regulator of IL12p35 and IL12p40 transcription (14) (15) (16) (17) and has a central role in the differentiation of CD8 + cDC and plasmacytoid DC (pDC) populations. Furthermore, produc tion of IL12 in T. gondii infection is dependent on IRF8 (11). IRF8 / mice lack the CD8 + and pDCs, although they have CD11c + CD8  cDCs (18) (19) (20) (21) . Moreover, in these mice, the residual IRF8 / cDCs display impaired responsiveness to TLRmediated signals and fail to produce IL12p40 (18) . Thus, IRF8 is essential for both IL12 production by myeloid cells including cDCs and the development of CD8 + cDCs that likely represent an IL12-producing DC subsets during T. gondii infection.
We initially studied the dynamic interaction of IRF8 with chromatin in live cells using fluorescence recovery after photobleaching (FRAP) analysis, a method that was recently applied to the study of IRF8-chromatin interactions (22) . For these studies, IRF8 / Tot2 cells were stably transduced with IRF8GFP that localizes to the nucleus. In the nucleus, IRF8GFP is present in two functionally distinct forms: a fraction of lowmobility IRF8 molecules engaged in interac tions with chromatin and a pool of highly mobile, unbound IRF8. As depicted in Fig. 3 , in untreated IRF8transduced Tot2 cells, a small fraction of immobile chromatinbound IRF8 molecules was present, and 80% of the initial fluores cence signal is recovered within 4 s after photobleaching. When cells were stimulated with LPS and IFN that favored IRF8-chromatin interaction, an increase in the immobile IRF8 pool, and a consequent reduction of the highly mobile unbound IRF8 fraction, occurred, resulting in significantly slower fluorescence recovery. In these samples, only 60% of the recovery occurred within the first 4 s of analysis, and the maximal recovery achieved was 70% of initial signal com pared with 90% observed in untreated cells (Fig. 3 , red vs. black line). Treatment with CT, but not CTB, before stimu lation with LPS and IFN produced a recovery curve similar to that of unstimulated cells (Fig. 3, B and C) . Similar to what we observed with CT, cells pretreated with the G proteinindependent adenylate cyclase activator forskolin or the membranepermeable cAMP analogue dbcAMP and stimu lated with LPS and IFN displayed a quick recovery of fluo rescence (Fig. 3, E and F) . Importantly, treatment with CT, CTB, forskolin, or dbcAMP alone did not alter the kinetics of fluorescence recovery (Fig. 3, A and D) . IRF8GFP was not overexpressed in IRF8 / Tot2 cells because levels were (B) CT and dbcAMP, but not CTB, inhibited IRF8, but not IRF1 or TFIIB, interaction with the mouse IL-12p40 promoter. A biotinylated DNA probe corresponding to the 81 to 24 region of the mouse IL-12p40 promoter encompassing the ISRE-like sequence, and a biotinylated mutant probe containing substitution (indicated by the lower case letters) in the context of the ISRE-like element were conjugated with streptavidin-bound magnetic beads and incubated with 500 µg of nuclear extracts from RAW 264.7 cells stimulated for 4 h as indicated. CT, CTB (both at 20 ng/ml), and dbcAMP (100 µM) were added 1 h before addition of LPS (1 µg/ml) and IFN- (100 ng/ml). Bound material was eluted, separated by 10% SDS-PAGE, and detected by Western blot analysis using rabbit anti-IRF8 antibody. (C) CT or dbcAMP did not modify the total amount of IRF8 or IRF1 in the nucleus. 500 µg of nuclear extracts were analyzed to measure the presence of IRF8 or IRF1 by SDS-PAGE Western blot. Membranes were stripped and reblotted to verify equal protein loading using an antinucleolin antibody. below those of endogenous IRF8 in a macrophage cell line (22) . Collectively, these data indicate that increased levels of cAMP, secondary to CTinduced Gs protein ADP ribosyl ation, impair the ability of IRF8 to bind to chromatin, and therefore to interact with its target promoters. Interestingly, IRF8 amplifies the transcription of its own gene (23) . Thus, the cAMPdependent inhibition of IRF8 binding to its own promotor would lead to reduced IRF8 mRNA expression, a concept that is consistent with prior studies showing cAMP dependent IRF8 mRNA downregulation (24, 25) .
CT inhibits IRF8 binding to the IL-12p40 promoter and its interaction with IRF1 IRF8 together with IRF1 has been reported to enhance IL12p40 gene transcription induced by LPS and IFN by forming a heterocomplex that interacts with a cisacting ele ment resembling the ISRE (IFNstimulated response ele ment; ISRElike) located in the IL12p40 mouse promoter (15, 26) . To assess if CT inhibits DNA-IRF8 interaction spe cifically at the level of the IL12p40 promoter, we performed a DNA affinity binding assay using a biotinylated IL12p40 promoter sequence containing the native ISRElike element conjugated to streptavidin beads (Fig. 4 A) . As shown in Fig. 4 B, IRF8 in nuclear extracts from RAW 264.7 cells stim ulated with LPS and IFN bound to the probeconjugated beads, and this binding was completely abrogated when cells were pretreated with CT, but not CTB. Moreover, a simi lar inhibitory effect was exerted by dbcAMP. Significantly reduced binding of IRF8 to a probe carrying a mutation in the ISRElike element was observed (Fig. 4 B, lane 6 ) indi cating that IRF8 binding was dependent on the integrity of the ISRElike element.
The same ISRElike element is a consensus sequence for IRF1 (26), therefore we investigated the effect of CT or dbcAMP on the ability of IRF1 to interact with the IL12p40 promoter. Similar to IRF8, stimulation with LPS and IFN induced IRF1 binding; however, neither CT nor dbcAMP reduced such interaction. Moreover, binding of TFIIB, a com ponent of the RNA polymerase II complex, to the TATA box element included in the probe sequence, was unaffected by CT treatment, indicating that the inhibition exerted by CT and dbcAMP was specific for IRF8. Moreover, similar levels of IRF8 and IRF1 were detected in nuclear extracts of all cells stimulated with LPS and IFN, indicating that observed effects were not caused by reduced IRF8 expression in the nucleus (Fig. 4 C) .
The concomitant ability of IRF1 and inability of IRF8 to bind to the IL12p40 promoter in cells treated with CT or dbcAMP prompted us to determine whether CT treatment 
pDC differentiation (Fig. 5 C) , indicating that this effect of CT is dependent on the CTA activity. Consistent with these results, and similar to our findings with CD8 + DCs, pDCs were preferentially lost after CT treatment in vivo (Fig. 5 D) . The ability of CT to inhibit the differentiation of pDCs from FLT3L-treated bone marrow and to induce pDC depletion in vivo is consistent with the hypothesis that IRF8-DNA inter action is a major target of CT activity.
In summary, our findings indicate that CT can inhibit IL12 production in vivo after infection with T. gondii, or systemic administration of LPS. In addition, we identify the inhibition of IRF8 function as a major molecular mechanism by which CT and other cAMPinducing agents prevent IL12 production in vitro and in vivo. Furthermore, we demonstrate that the CTinduced block of IRF8 function is associated with impaired IRF1-IRF8 heterocomplex formation that is inde pendent of the phosphorylation state of IRF1. Finally, by blocking IRF8 function, CT may simultaneously inhibit IL12p40 mRNA expression in macrophages and differenti ated DCs and interfere with normal differentiation of CD8 + DCs (and pDCs) that represent a primary source of IL12, at least under certain stimulation conditions.
MATERIALS AND METHODS
Mice and cell lines. 8-12wkold conventionally housed female BALB/c mice were obtained from the National Cancer Institute and were used as ap proved under animal study protocol LMI11E by the National Institute of Allergy and Infectious Disease/National Institutes of Health (NIH) Animal Care and Use Committee. The derivation and maintenance of IRF8 / Tot2 cells and their transfection with IRF8GFP were previously described (30) . The mouse macrophage cell line RAW 264.7 was purchased from American Type Culture Collection (ATCC).
Cell culture and measurement of cytokines. CD11c + splenocytes were isolated using anti-mouseCD11c immunomagnetic beads (Miltenyi Biotech). Human monocytes were obtained by counterflow centrifugationelutriation of blood collected from normal blood donors under the NIH Institutional Review Board-approved human subjects protocol 99cc0168. Monocyte derived DCs were obtained by culturing purified human monocytes in GMCSF and IL4, as previously described (5) . The mouse macrophage cell line RAW 264.7 was and stimulated at 80% confluence. CD11c + spleno cytes, human blood monocytes, monocytederived DCs (MoDC), or the RAW 264.7 cells were cultured at 1-2 × 10 6 cells/ml in RPMI1640 and supplemented with 10% FCS, 100 µg/ml penicillin, 100 µg/ml streptomy cin, 50 µg/ml gentamicin, 5% NCTC109 media (all from Invitrogen), 15 mM Hepes, and 200 mM glutamine (cRPMI) at 37°C and 5% CO 2 with various stimuli as indicated. CT was purchased from List Biological Labora tories. Staphylococcus aureus, Cowan's strain I (SAC; Pansorbin) was obtained from Calbiochem. Recombinant mouse IFN was obtained from BD. LPS (from Escherichia coli, serotype 0127:B8) and salbutamol were purchased from SigmaAldrich. Anti-mouse-IL12 (clone C17.6) was originally provided by G. Trinchieri (National Cancer Institute, Bethesda, MD). CGS21680 and ZM241385 were obtained from Tocris Bioscience. Cytokine levels in cell culture supernatants and mouse sera were measured by ELISA using standard kits (BD). ELISA lower limit of detection was 50 pg/ml for IFN and IL12 p70 and 30 pg/ml for IL12 p40.
T. gondii infection. T. gondii cysts (ME49 strain) were prepared from brains of infected mice as previously described (31) . BALB/c mice were untreated or treated with two doses of CT (5 µg) or anti-IL12 antibody (1.8 mg) given could inhibit the formation of the IRF1-IRF8 heterocom plex. Consistent with this possibility, CT markedly reduced the amount of nuclear IRF1-IRF8 complex induced by LPS and IFN (Fig. 4 D) . Tyrosine phosphorylation of IRF1 is a crucial event for IRF1-IRF8 complex formation (27) . How ever, the amount of phosphorylated IRF1 induced by LPS and IFN was not modified by CT (Fig. 4 E) . This indicates that the ability of CT to block IRF1-IRF8 complex forma tion is not caused by impaired IRF1 phosphorylation.
Together with IL12 suppression, CT can enhance the ability of TLR ligands to induce DC production of IL6, IL1, and IL10, while inhibiting their production of TNF (4). We confirmed the ability of CT and dbcAMP to inhibit the production of IL12 and TNF, but not IL10, in human peripheral blood monocytes, monocytederived DCs, and the RAW 264.7 cell line stimulated with LPS and IFN (Fig. S4) . Interestingly, recent data indicate that TNF gene transcription in mouse macrophages is also regulated by IRF1 and IRF8 (28) . Therefore, it is feasible that the mechanism by which CT and cyclic AMP blocks TNF production is also caused by effects on IRF1-IRF8 interactions. The molecular events triggered by CT that lead to reduced IRF1-IRF8 inter action remain unclear. In addition to IRF1, IRF8 has been reported to form heterocomplexes with other binding part ners, including NFAT and PU.1. Interference with physical interaction between these proteins and IRF8 might regulate its ability to associate with DNA and IRF1. In support of this possibility, increased cAMP levels have been reported to in hibit NFAT activity (29) . PKAdependent phosphorylation of NFAT increased 14-33 binding and reduced NFAT tran scription activity at the IL2 promotor. Whether CT and other cAMP inducers might affect such interactions is currently under investigation in our laboratories.
CT blocks the differentiation of pDCs from bone-marrow cells cultured with fms-related tyrosine kinase 3 ligand (FLT-3L) in vitro and mouse spleen cells in vivo
Results of the FRAP analysis indicate that CT induces a gen eral inhibition of IRF8 function, suggesting that other IRF8 dependent processes might also be affected. IRF8 plays a key role not only in the activation of IL12p35 and p40 genes, but also in the normal development of pDC and CD8 + cDC populations in vivo (18) (19) (20) (21) . Moreover, IRF8deficent bone marrow cells fail to differentiate into pDCs when cul tured in the presence of FLT3L in vitro (21) . We therefore studied the effect of CT on the generation of pDCs from FLT3L-stimulated bone marrow cultures. In keeping with previous reports, after culture with FLT3L, one third of mouse bone marrow cells differentiated into CD11c + CD11b  cells that also expressed B220 and Ly6c and could therefore be identified as pDCs (Fig. 5 A) . In the presence of CT, we observed a dramatic reduction of the CD11c + CD11b  subset (from 34.6 to 4.28%), and a concomitant increase in the CD11c + CD11b + population. In addition, only 50% of the re maining CD11c + CD11b  cells expressed Ly6C (Fig. 5 B) . Conversely, exposure to CTB did not alter FLT3L-induced Bone marrow-derived pDCs. Bone marrow from 6wkold mice was cultured at 5 × 10 5 cells/ml in DMEM (Biofluids, Inc.) supplemented with 10% fetal bovine serum and containing 100 ng/ml recombinant human FLT3L (PeproTech). Medium together with FLT3L was changed at days 3 and 6 of culture. CT or CTB was added at 20 ng/ml final concentration at the beginning of the culture and at every medium change. After 9 d, cells were analyzed by flow cytometry using fluorochromeconjugated monoclo nal antibodies against CD11c, CD11b, B220, and Ly6C (BD).
Statistical analysis.
Results represent the mean ± SD where applicable. Statistical significance of differences was determined by the Student's t test.
Online supplemental material. Fig. S1 demonstrates the regulation of IL12 production from murine cDCs by the  2 adrenergic agonist Salbuta mol, the adenosine A2a receptor agonist CGS21680, the adenosine A2a receptor antagonist ZM241385 and CT. Fig. S2 shows the time course of CD8 + cDC loss as well as annexin V staining of CD8 + cDCs after CT administration in vivo. Fig. S3 demonstrates the effect of CT dose on CD8 + DC loss, and the effect on IL12 and IFN production in vivo. Fig. S4 demonstrates the effect of CT and dbcAMP on IL12, TNF, and IL10 production from human monocytes, monocytederived DCs, and RAW 264.7 cells. Online supplemental material is available at http://www.jem .org/cgi/content/full/jem.20080192/DC1. i.p. at 3d intervals. Mice were infected with 100 cysts given i.p. 1 d after the first dose of CT or anti-IL12. The percentage of infected peritoneal exudate cells was determined using stained cytospin preparations. 500 cells were counted for each sample. 5 d after infection with T. gondii, blood was col lected from individual mice for cytokine quantification.
FACS analysis. Spleen cells, or CD11c + enriched splenocytes were ana lyzed by flow cytometry using antibodies for cDCs (antiCD11c, HL3), B cells (antiCD19, 1D3), T cells (antiCD3, 1452C11, antiCD4, GK1.5, antiCD8, Ly2), and pDCs (antiB220, RA36B2, antiLy6C, AL21, mPDCA1, JF051C2.4.1; all from BD). Labeled cells were analyzed using a FACSCalibur flow cytometer (BD), and data was analyzed using FlowJo software (Tree Star, Inc.).
FRAP. FRAP for IRF8chromatin interactions was performed on IRF8
GFP-transduced IRF8 / Tot2 cells as previously described (22) . Tot2 cells plated on a chambered coverslip in 1% methylcellulose (MethoCult; Stem Cell Technologies) were kept at 37°C by using an air stream stage incubator (ASI 400; Nevtek). Livecell imaging was performed on a 510 confocal micro scope (Carl Zeiss, Inc.) by using the 488nm line of an Ar laser with a 100×, 1.3numerical aperture oil immersion objective. Photobleaching was per formed on a small circular area (0.5µm radius, 25 pixels) in the nucleus at the maximum laser power. 30 prebleach images were acquired before a bleach pulse of 115 ms. Fluorescence recovery was monitored at low laser intensity (0.2% of a 45mW laser) at 45ms intervals for 16 s. FRAP experiments were performed on at least 15 independent cells, and data were averaged to gener ate a single FRAP curve. FRAP data obtained using cells before and after stimulation with LPS+IFN were analyzed to fit to the recently developed mathematical binding models to confirm and support our initial hypothesis on the two fractions of IRF8 (32) .
DNA affinity binding assay and immunoprecipitation. Nuclear ex tracts from RAW 264.7 cells were obtained using NEPER extraction kit following manufacturer's instructions. 5Biotinlabeled DNA sequence corresponding to the 81 to 24 region of the murine IL12p40 promoter containing a known ISRElike element, as well as a control sequence con taining a substitution mutation in the region of the ISRElike element were purchased from Invitrogen. Biotinlabeled probes were conjugated to 200 µg of streptavidincoated magnetic beads (Dynabeads M280 streptavidin; Dynal) in TrisEDTA buffer (pH 7.9) and were blocked with 0.5% bovine serum albumin in TGED buffer (10 mM Tris-HCl, pH 8.0, 10% vol/vol glycerol, 0.1 mM ethylenediaminetetraacetic acid, and 0.01% Triton X100) overnight at 4°C. The mixtures of probeconjugated beads and 500 µg of nuclear extracts in 500 µl of TGED with the final concentration of NaCl at 100 mM were subsequently incubated at 4°C for 4 h. Beads were extensively washed with TGED buffer, and DNAbound proteins were eluted using TGED with 1 M NaCl. Proteins were separated by SDSPAGE for immuno blot detection with rabbit antiIRF8 antibody. For coimmunoprecipita tions, 500 µg of nuclear extracts from RAW264.7 cells diluted 1:3 with wash buffer (50 mM TrisHCl, 1 mM PMSF, Complete protease inhibitor cock tail [Roche] , and phosphatase inhibitor cocktail 1 and 2 [SigmaAldrich]) were incubated with mouse monoclonal antiIRF1 (2.5 µg/sample; Santa Cruz Biotechnology, Inc.) or irrelevant IgG over night at 4°C in a rotator and recovered with 25 µl of G protein-conjugated magnetic beads (Active Motifs). Samples were subjected to SDSPAGE and Western blot analysis with rabbit antiIRF8 or rabbit antiIRF1 (Santa Cruz Biotechnology). For determining IRF1 phosphorylation, mouse antiphosphotyrosine monoclo nal cocktail (5 µl/sample, 4G10; Millipore) or 2.5 µg of irrelevant IgG were incubated overnight at 4°C with 25 µl G protein-conjugated magnetic beads. Beads were then washed twice with icecold PBS and incubated (90 min at 4°C in a rotator) with 1 mg of nuclear extract. After extensive washing, samples were subjected to SDSPAGE and Western blot analysis with rabbit antiIRF1 antibody (Santa Cruz Biotechnology, Inc.).
